ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
- 31 May 2012
- journal article
- case report
- Published by Elsevier BV in Lung Cancer
- Vol. 76 (2), 253-254
- https://doi.org/10.1016/j.lungcan.2012.02.003
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Carcinoma Meningitis Secondary to Non–Small Cell Lung CancerArchives of Neurology, 1998